All cells, whether big or small, short or long, rely on proteins to function properly. In most cells, transporting these proteins is relatively simple. Neurons in the brain, however, face a ...
Drug-resistant epilepsy affects millions of people worldwide and remains one of the most difficult neurological disorders to treat. For patients whose seizures continue despite medication, surgical ...
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-1181 ...
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer ...
New cancer trial: Merck and Erasca will test ERAS-0015 with Keytruda in RAS-mutant solid tumors under the AURORAS-1 study. Potential treatment boost: The combination targets tumor pathways and immune ...
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients ...
Once-daily vosoritide improved annualized growth velocity at 1 year for children with five different genetic subtypes of ...
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...
Daraxonrasib shows strong survival gains in trials, prompting FDA to open rare early access for advanced pancreatic cancer ...
Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” paradigm and enabling inhibitors that engage previously hidden pockets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results